Descripción del proyecto
Un modelo de matriz celular tridimensional para el descubrimiento de antidiabéticos
La demanda de antidiabéticos sigue aumentando, ya que se calcula que la prevalencia de la diabetes en adultos alcanzará la cifra de 629 millones de personas afectadas para el 2045. Por lo tanto, existe una necesidad urgente de desarrollar antidiabéticos más eficaces, hecho que se ve obstaculizado por la escasa previsibilidad de los modelos actuales para identificar compuestos cabeza de serie durante el descubrimiento de fármacos. El proyecto financiado con fondos europeos Cells in Matrix está desarrollando el «micropáncreas artificial», un modelo tridimensional para la investigación y el desarrollo de antidiabéticos. Se basa en un cultivo tridimensional de células derivadas del páncreas y células beta pancreáticas humanas y ofrecerá una aceleración y reducción de costes en el desarrollo de antidiabéticos. El sistema de micropáncreas artificial ofrece una mayor vida útil y funcionalidad para estudios en profundidad sobre el modo de acción, la validación, la toxicología y la farmacocinética «in vitro» de las moléculas farmacéuticas, lo que permite una mayor previsibilidad y fiabilidad.
Objetivo
The demand for diabetes drugs keeps increasing as adult Diabetes prevalence reached 425 million people in 2017 (1 in 11 adults) and is estimated to rise to 629 million till 2045. The market of Diabetes drugs is expected to reach €80.5 Billion in 2019 while the investment in Diabetes drug development is ~ €4 Billion (CAGR of 13%). There is a constant need for more effective diabetes medications, hampered by the poor predictability of the current systems for identification of lead compounds during drug discovery. The failure rate of new drugs development is about 90% and the cost for reaching the
market with a new drug is ~ €1 Billion.
Cells in Matrix Project develops an innovative 3D model for R&D of Diabetes Drugs , an Engineered Micro Pancreas (EMP) based on organ-derived 3D cell culture and human sourced insulin producing cells as an innovative tool for accelerating and cost reduction of Diabetes drug development. EMP system offers significantly extended shelf life and function for in-depth studies of drug molecules mode of action, validation, toxicology and in vitro pharmacokinetics, rendering higher prediction reliability.
Cells in Matrix disruptive technology creates market added value to all the stakeholders, especially pharma industry, by improving compound screening at least X4 (from 5% rate of success today to at least 20%), resulting in cost saving that could reach €100 million per innovative new drug development.
The project receives strong interest from stakeholders and plans immediate commercialization of the product to direct endusers, including academia and pharma companies, such as Boehringer Ingelheim.
The FTI funding will enable market entry and validation & support external fundraising for the wider penetration of the global drug discovery market. Betalin Therapeutics and Kugelmeiers, the project commercial leading partners will share the growth and revenues gained by its commercial success.
Ámbito científico
- medical and health sciencesbasic medicinepharmacology and pharmacydrug discovery
- medical and health sciencesbasic medicinepharmacology and pharmacypharmaceutical drugs
- medical and health sciencesclinical medicineendocrinologydiabetes
- medical and health sciencesbasic medicinepharmacology and pharmacypharmacokinetics
- medical and health sciencesbasic medicinetoxicology
Programa(s)
Régimen de financiación
IA - Innovation actionCoordinador
5268101 Ramat Gam
Israel
Organización definida por ella misma como pequeña y mediana empresa (pyme) en el momento de la firma del acuerdo de subvención.